Lysyl oxidase is downregulated by the EWS/FLI1 oncoprotein and its propeptide domain displays tumor supressor activities in Ewing sarcoma cells.
Ewing sarcoma is the second most common bone malignancy in children and young adults. It is driven by oncogenic fusion proteins (i.e. EWS/FLI1) acting as aberrant transcription factors that upregulate and downregulate target genes, leading to cellular transformation. Thus, identificating these targe...
Guardado en:
Autores principales: | Noelia Agra, Florencia Cidre, Laura García-García, Juan de la Parra, Javier Alonso |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/fc93598711a441c2ab01dba8774a1347 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
USP19 deubiquitinates EWS-FLI1 to regulate Ewing sarcoma growth
por: Maria E. Gierisch, et al.
Publicado: (2019) -
BCL11B is up-regulated by EWS/FLI and contributes to the transformed phenotype in Ewing sarcoma.
por: Elizabeth T Wiles, et al.
Publicado: (2013) -
A polypeptide from the junction region sequence of EWS-FLI1 inhibits Ewing’s sarcoma cells, interacts with the EWS-FLI1 and partner proteins
por: Krishna Priya Thangaretnam, et al.
Publicado: (2017) -
EWS–FLI1‐targeting peptide identifies Ewing sarcoma tumor boundaries and lymph node metastasis via near‐infrared imaging
por: Yu Wang, et al.
Publicado: (2021) -
An in situ activity assay for lysyl oxidases
por: Huilei Wang, et al.
Publicado: (2021)